Gerri Henwood
-
After Net Loss of Nearly $50 Million, Malvern-Based Pharma Company Completes Public Stock Offering
Malvern-based pharmaceutical company Baudax Bio has completed $5 million in stock sales, writes John George for the Philadelphia Business Journal. The proceeds made from the…
-
Veteran of Life Sciences Industry Replaces Founder of Malvern-Based Recro Pharma as CEO
Malvern-based Recro Pharma has named David Enloe its new president and CEO, writes John George for the Philadelphia Business Journal. Enloe replaces the company’s founder…
-
Malvern’s Baudax Bio Closes $50 Million Loan Deal to Officially Launch Its Non-Opioid Pain Med
Malvern-based Baudax Bio has signed a loan deal with Marathon Asset Management worth $50 million to support the launch of its intravenous and non-opioid pain…
-
Malvern’s Baudax Bio Turns to Nontraditional Methods to Promote New, Non-Opioid Pain Med
Baudax Bio launched its new, non-opioid pain medication earlier this week, but due to the ongoing coronavirus crisis, the Malvern-based company is relying on non-traditional…
-
Malvern-Based Recro Pharma Sees Its Stock Plummet 34 Percent
Malvern-based Recro Pharma saw its stock plunge by more than 34 percent after the Food and Drug Administration rejected its new drug application for a…
-
FDA Rejects Malvern-Based Recro Pharma’s Application for Non-Opioid Pain Med
Recro Pharma’s stock took a major hit after the FDA rejected a new drug application for the Malvern company’s non-opioid pain medication, writes John George…
-
Malvern’s Recro Pharma Secures Nine-Figure Line of Credit
Malvern’s Recro Pharma has secured a line of credit worth $100 million from funds managed by Athyrium Capital Management, writes John George for the Philadelphia…
-
Malvern’s Recro Pharma Buys Non-Opioid Pain Treatments from Ivy League College
Recro Pharma is injecting some new prospects into its effort to alleviate surgical patients’ pain without the use of addictive opioids. The Malvern pharmaceutical company…
-
Malvern’s Recro Pharma to Use Stock Proceeds on Potential Commercial Launch
Malvern’s Recro Pharma is already preparing for the potential commercial launch of its highly anticipated new drug with a $35.9 million public stock offering, writes…
-
Test Results on Non-Opioid Pain Med Bode Well for Malvern’s Recro Pharma
Recro Pharma’s latest drug test felt more like a shot of adrenaline than a sigh of relief when patients noted they were well aware of…
-
Chester County Daily News: Business Briefs
VISTA Today’s Business Briefs keep you informed about what’s happening around the county. Lamb McErlane Attorney Selected As New Secretary for Lundale Farm West Chester…
-
Chester County Daily News Business Briefs
VISTA Today Daily News Business Briefs are concise stories that bring you up to date with what’s going on around Chester County. This morning: Wolf…
-
Malvern’s Recro Pharma Prepping To Inject Second Pain Product Into Market
The promise of bringing pain relief to patients right out of surgery without using narcotics is another step closer to reality for a Malvern specialty…
-
Recro Pharma is on Track for Success
Recro Pharma Inc. (NASDAQ:REPH) released its fourth quarter and full year financial results for the period ending December 31, 2014 last month. The clinical stage pharmaceutical…
-
Recro Pharma Restarting Trial For Post-Surgery Pain Drug
A clinical drug study by Malvern’s Recro Pharma is being refined to better differentiate the pharmaceutical, an intranasal form of dexmedetomidine called Dex-IN, from its placebo…
-
Recro Pharma Reports Second Quarter Financials
Recro Pharma, Inc. of Malvern says the clinical stage specialty pharmaceutical company is on track to report top-line data from a Phase IIb clinical trial…
-
Recro Pharma Gains Russell Index Status
While some analysts thought Recro Pharma, Inc. of Malvern would face an uphill battle against pharmaceutical giants such as Johnson and Johnson, news continues to…
-
Recro Pharma Begins Clinical Trial Of Non-Opioid Dex-IN
Bunions hurt, and recovery from bunion surgery can take five months, but the Malvern specialty pharmaceutical company Recro Pharma announced they have just taken significant…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
